TL;DR
This paper reports a novel de novo variant in the NALCN gene in a Chinese infant diagnosed with CLIFAHDD syndrome. This finding expands the known spectrum of NALCN-related disorders and highlights the gene's critical role in neurodevelopment.
What Problem Does This Paper Address?
The NALCN gene encodes a sodium ion leak channel crucial for nerve resting conductance and excitability. Variants in NALCN are known to cause two neurodevelopmental disorders: CLIFAHDD (congenital contractures of the limbs and face, hypotonia, and developmental delay) and IHPRF (infantile hypotonia with psychomotor retardation and characteristic facies). While CLIFAHDD is typically inherited in an autosomal dominant manner and IHPRF in an autosomal recessive manner, the precise mechanisms and the full spectrum of NALCN-associated phenotypes are still being elucidated. This study aims to contribute to this understanding by identifying and characterizing a new NALCN variant in a patient with CLIFAHDD.
Methods
The researchers employed Whole-Exome Sequencing (WES) on DNA extracted from the peripheral blood of the affected infant and his parents. This technique allows for the sequencing of all protein-coding regions of the genome. The WES data was then analyzed using standard bioinformatics pipelines, including mapping reads to the human reference genome, removing PCR duplicates, and annotating variations according to ACMG guidelines. To confirm the identified variant and its inheritance pattern, Sanger sequencing was performed. The parent-child relationship was also confirmed using King software to establish the de novo origin of the variant.
Datasets
The primary dataset used in this study is the whole-exome sequencing data from a Chinese infant and his parents. This trio-based approach is crucial for identifying de novo mutations. The identified variant was also cross-referenced against public databases like gnomAD exomes and genomes to assess its frequency in the general population.
Key Insights and Ideas
- Expanding the NALCN Variant Spectrum: The identification of a novel de novo variant (c.4300A>G, p.I1434V) in NALCN in a Chinese infant with CLIFAHDD directly contributes to the growing list of known disease-causing variants for this gene.
- Clinical Phenotype Variability: The study highlights the significant variability in clinical presentation even within the same NALCN-related disorder. While hypotonia is a common feature of CLIFAHDD, this particular infant did not exhibit it, underscoring the need for comprehensive genetic analysis beyond just clinical symptoms.
- Potential for Gain-of-Function in CLIFAHDD: The paper suggests that gain-of-function variants in NALCN might be responsible for CLIFAHDD, contrasting with loss-of-function variants that are implicated in IHPRF. This distinction is crucial for understanding the underlying molecular mechanisms.
- BPTF Variant as a Red Herring: The identification of a BPTF variant (c.1117A>G, p.T373A) in the infant, classified as a VUS (Variant of Uncertain Significance), was considered but ultimately deemed unlikely to be the causal variant due to distinct clinical features associated with BPTF mutations.
Key Results
- A novel de novo missense variant in the NALCN gene, c.4300A>G (p.I1434V), was identified in a Chinese infant diagnosed with CLIFAHDD syndrome.
- Sanger sequencing confirmed that this variant was heterozygous in the affected child and absent in his parents, establishing its de novo origin.
- The variant was not found in the gnomAD exomes or genomes databases, suggesting it is rare.
- Computational analysis predicted the variant to be pathogenic or damaging, with an ACMG classification of "likely pathogenic."
- The affected infant presented with facial contractures, arthrogryposis, and developmental delay, but notably, no hypotonia.
- MRI revealed abnormally broadening bilateral temporal extracranial space, left frontal subdural effusion, and a cyst in the right choroid plexus.
Limitations and Future Work
- Limited Sample Size: As a case report, the findings are based on a single patient, limiting the generalizability of the results.
- Uncertainty of Cyst Significance: The clinical significance of the choroid plexus cyst in relation to the NALCN variant and developmental delay remains unclear, as the parents refused further examination.
- Future Research Directions: The authors emphasize the need for further studies to explore the detailed mechanisms by which NALCN variants lead to CLIFAHDD, particularly the gain-of-function hypothesis. Additionally, exploring potential therapeutic interventions, such as the use of 2-aminoethoxydiphenyl borate or flunarizine, which have shown promise in C. elegans models, warrants further investigation for clinical implementation. The expansion of the clinical range of NALCN-related disorders is also a key future direction.
Summary updated